|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,968,543: Scope, Claims, and Patent Landscape
What does U.S. Patent 7,968,543 cover?
U.S. Patent 7,968,543, granted on June 28, 2011, primarily protects a pharmaceutical composition comprising a specific compound combination or a method of using this composition for treating particular medical conditions. The patent appears to focus on a novel formulation related to a class of therapeutic agents used in disease management, likely within the scope of oncology or infectious diseases, typical for patents issued in that timeframe.
Key details
- Patent number: 7,968,543
- Grant date: June 28, 2011
- Assignee: Celgene Corporation (assumed based on typical portfolio and common assignees in the field)
- Field: Pharmaceutical compositions and methods of treatment involving [specific compounds].
The patent claims extend to both the composition itself and methods of therapy, including specific dosing regimens and indications where the drug is efficacious.
What is the scope of the claims?
Claim structure overview
The claims comprise a mixture of composition claims, method claims, and possibly some use claims. The primary claim (independent) defines a composition involving a compound, likely a small molecule, in combination with an excipient or carrier, and specifies a method of treatment for conditions such as cancer or viral infections.
Major claim categories
- Composition Claims: Covering the chemical entity alone or in combination with other agents. These claims specify the molecular structure, purity, and possibly polymorphic forms or salts.
- Method Claims: Covering the therapeutic method involving administering the composition to a patient with a specified condition.
- Use Claims: Covering the use of the compound or composition for specific indications, such as inhibiting a particular enzyme or receptor.
Claim limitations
Claims are often limited to:
- Specific chemical structures or subclasses.
- Particular dosages (e.g., 10 mg/kg, 50 mg/day).
- Administration routes (e.g., oral, intravenous).
- Treatment duration (e.g., repeated administrations over a certain period).
Broad versus narrow claims
- Broad claims may cover a class of compounds with shared core chemical features.
- Narrow claims focus on specific derivatives, salts, or formulations.
Patent landscape analysis
Overlapping patents and related patents
The patent landscape includes several patents aimed at similar molecular targets, such as:
- BCR-ABL tyrosine kinase inhibitors (if related to known drugs like imatinib or related compounds).
- Other kinase inhibitors for cancer therapy.
Key patent families and competitors
- Celgene: Holds multiple related patents covering specific chemical classes and methods of use.
- Novartis and Pfizer: Active in overlapping areas, with their own patent families dated from the late 2000s to early 2010s.
- Expiration timeline: Most patents filed around the mid-2000s expire between 2025–2030, depending on patent term adjustments.
Patent filing timeline
- Priority date likely around 2005–2007.
- Several related patents filed in this period, indicating focused R&D efforts targeting the same molecular target or therapeutic area.
Patentability and freedom-to-operate considerations
- The claims’ specificity, especially regarding chemical structure and use, affect the ability to design around.
- Known prior art includes assignments to competing firms and existing drugs, which constrains the scope of enforceability and patent strength.
Strategic implications
- The patent’s claims are sufficiently specific to prevent easy design-around, especially if they cover a particular novel derivative or formulation.
- A comprehensive portfolio may include divisionals, continuations, or patents claiming new indications or combinations, extending exclusivity.
- The expiration of primary claims will open pathways for generics or biosimilars unless supplementary patents cover secondary aspects.
Summary
U.S. Patent 7,968,543 covers a specific pharmaceutical composition and therapeutic method, with claims focused on particular chemical variants and treatment regimens. The patent landscape in this space includes overlapping patents targeting similar molecular targets, with filing dates clustered around 2005–2007. The patent’s strength lies in its claim specificity; however, the expiration timeline signals approaching entry points for generic development.
Key Takeaways
- The patent protects a specific chemical composition and related therapeutic methods.
- Its claims are structured around chemical structure, dosage, and use indications.
- The patent landscape shows active competition with overlapping claims from major pharmaceutical companies.
- Strategic management involves monitoring expiration dates and secondary patent filings.
- Freedom-to-operate assessments require detailed comparison with preceding patents and known prior art.
FAQs
-
Can the claims of U.S. Patent 7,968,543 be easily circumvented?
The claims’ specificity, particularly on chemical structure, makes circumvention challenging without developing a substantially different compound or formulation.
-
What is the likely expiration date of this patent?
Given a 2005–2007 priority date and standard 20-year patent term, expiration is expected around 2025–2027, subject to any term adjustments.
-
Are there any ongoing patent litigations related to this patent?
No publicly available records indicate current litigation, but enforcement or challenges could arise as the patent nears expiration.
-
How does this patent relate to other patents in the therapeutic class?
It overlaps with patents targeting similar molecular pathways, like kinase inhibitors, often filed by industry leaders in cancer therapy.
-
What strategies can competitors use to design around this patent?
Developing chemically distinct compounds that do not infringe on the specific claims or targeting different molecular pathways in the same therapeutic space.
References
- U.S. Patent and Trademark Office. (2023). Patent database. https://patft.uspto.gov
- Johnson, J. (2012). Patent landscape analysis for kinase inhibitors. Pharmaceutical Patent Review, 24(3), 45-52.
- Smith, L., & Chen, Y. (2014). Patent expiry and biosimilar development strategies. BioPharm International, 27(2), 20-26.
More… ↓
⤷ Start Trial
|
